🤝SciNovate continues to drive innovation, offer opportunities for learning, and boost our efforts toward reimagining medicine to improve people's lives! As part of the SciNovate series we organize at TRD Mengeš to foster academic collaborations, we hosted the head of Biomedical Sciences Institute, University of Maribor, Dr. Uroš Maver. His lecture centered on the development of a complex in vitro model in drug development. Combining components of the ADME system (Absorption, Distribution, Metabolism, Excretion), the model seeks to mirror human physiology more closely, and can be applied to all stages of drug development. This innovative approach could reshape research methodologies and unlock new treatments. 🙏We thank again professor Maver for sharing his insights into the latest research and advancements in the field, offering novel insights and sparking interesting discussions among attendees. 🌠Thanks to Novartis TRD Innovation Council (Mateja Kramer) and our local Novartis hosts Marina Klemenčič and Aleš Ručigaj for giving us a chance to broaden our horizons.
Novartis in Slovenia’s Post
More Relevant Posts
-
Earlier this week, our Executive Director, Nick Lench, participated in a panel discussion at the 24th Bio€quity Europe Conference in San Sebastián. Chaired by Selina Koch, PhD, Nick and fellow panellists Rowan Gardner and Emmanuelle Astoul discussed how to leverage Europe's extensive biomedical data resources to enhance drug discovery and development. "For rare diseases in particular, the UK and Europe have extensive genomic and clinical data that can be mined to validate targets, stratify patients and develop precision therapies." 🤝 Building collaborations and partnerships and the sharing of high-quality data sets are essential to drive translational research for the benefit of patients. BioCentury Inc. PrecisionLife Wellcome Sanger Institute #NATA #Research #Science #Innovation #AdvancedTherapies #RNATherapeutics #therapeutics #drugdiscovery #biotech #collaboration #partnership #TranslationalResearch #RareDiseases #PrecisionTherapy #PersonalisedTherapy
To view or add a comment, sign in
-
-
New paper published in Advanced Drug Delivery Reviews: 𝗠𝗼𝗱𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗶𝗺𝗺𝘂𝗻𝗲 𝘀𝘆𝘀𝘁𝗲𝗺 𝘁𝗼𝘄𝗮𝗿𝗱𝘀 𝗮 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗵𝗿𝗼𝗻𝗶𝗰 𝘄𝗼𝘂𝗻𝗱 𝗵𝗲𝗮𝗹𝗶𝗻𝗴: 𝗔 𝗯𝗶𝗼𝗺𝗮𝘁𝗲𝗿𝗶𝗮𝗹𝘀 𝗮𝗻𝗱 𝗡𝗮𝗻𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗽𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 Chronic wounds are known to present a complex scenario where inflammatory and infectious processes occur in an endless and self-amplifying loop. This review looks at how different immune cells help with healing and explores some of the most recent and promising strategies based on biomaterials and nanostructures to improve this process. Described innovations may be key to boosting the immune system and improving the healing of these stubborn wounds. Thanks to all the authors for your work! A joint effort between the University of the Basque Country (UPV/EHU) and Charité – Medical University of Berlin (chariteberlin): Kevin Las Heras Zapata, Itxaso García Orue, Fiorenza Rancan, Manoli Igartua Olaechea and Rosa Maria Hernandez Link: https://lnkd.in/d8EWEvie
To view or add a comment, sign in
-
-
Glyphic Biotechnologies is pioneering a shift in how America approaches medical research with its advanced protein sequencing technologies. 👇 This innovation is crucial for unlocking the potential of proteomics—the study of proteins at a large scale—which plays a key role in understanding human diseases and developing targeted treatments. As these technologies become more accessible and cost-effective, they facilitate the rapid progression of personalized medicine. This enhances the effectiveness of treatments and reduces the time and expense involved in medical research. This shift has the potential to position America as a leader in health innovation, setting new standards for medical research globally. These advancements have the potential to revolutionize patient care, making it more personalized and effective, thereby improving health outcomes across the board. At Harpoon Ventures, we're proud and excited to back the team at Glyphic Biotechnologies in their quest to make America a more strategic healthcare contributor to our planet. ⇀
To view or add a comment, sign in
-
-
🎖️Check out the Editor's Choice #Review "Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs" 👥by Virginia Metrangolo and Lars Engelholm Biotech Research & Innovation Centre (BRIC), University of Copenhagen Københavns Universitet - University of Copenhagen 🔗Link here: https://lnkd.in/evG8Bdif 🔶Antibody–drug conjugates (ADC) are targeted oncotherapeutics with the validated potential to create significant clinical impact. This comprehensive review covers the recent evolution of ADC design and development discussing molecular challenges and opportunities for further improvements.🔶
To view or add a comment, sign in
-
-
📃 New scientific #paper published in #Nature #ScientificReports by the InSyBio team, Politecnico di Torino, Industrial Systems Institute / Research Centre ATHENA, University of Applied Sciences and Arts of Southern Switzerland and 7HC! 🔬We are happy to present you #VirtuousPocketome, a computational tool designed to screen potential #protein-ligand interactions and identify similar binding sites based on these complexes. 🔎In this paper we showcase the potential of this publicly available pipeline in the case of the TAS2R46 receptor, complexed with strychnine, identifying 145 proteins with similar binding sites to this receptor! 🍽 This could lead to major advancements in the rationalization of the #diet as a supplement to standard #pharmacological treatments and the design of novel tastants-inspired compounds! ✍️ Congratulations to all the authors: Lorenzo Pallante, Marco Cannariato, Lampros Androutsos, Eric A. Zizzi, Agorakis Bompotas, Xhesika Hada, Gianvito Grasso, Athanasios Kalogeras, Seferina Mavroudi, @ Giacomo Di Benedetto, Konstantinos Theofilatos and Marco Deriu ℹ️ You can find the paper at: https://lnkd.in/egW9W4nh
To view or add a comment, sign in
-
At the beginning of the year, the Deutsche Forschungsgemeinschaft (DFG) - German Research Foundation and the German Council of Science and Humanities invited #MedST speaker Prof. Fabian Kiessling and Prof Laura De Laporte, as spokespersons for the TransMedMat Cluster of Excellence application, to prepare a corresponding full proposal for funding as part of the #ExcellenceStrategy 🚀. In line with this, the DWI – Leibniz-Institut für Interaktive Materialien, the Uniklinik RWTH Aachen and RWTH Aachen University have now launched the socalled Leibniz ScienceCampus "ACTISONO" (Sonopharmacology - Activation of drugs by ultrasound) 👏. https://lnkd.in/etYHhy4r In this interdisciplinary network, researchers from the fields of #chemistry, #biology, #medicine and #engineering are developing innovative technologies for the activation of active #pharmaceutical ingredients via #ultrasound. The researchers' vision and goal is the target-specific treatment of patients using ultrasound as an external trigger, for example to combat liver damage or bacterial infections. The researchers, who can already build on promising laboratory investigations, will initially work together for four years. The total funding of the Interdisciplinary DWI Leibniz ScienceCampus for Innovative Therapies amounts to about 3.6 million euros. The #ProfileAreas Community wishes this exciting research project every success! Photo: Martin Braun
To view or add a comment, sign in
-
-
How can we accelerate the delivery of innovative #health techniques and products to patients who need it? By working together to make cell, gene and tissue related therapies available to all European citizens! 💡 That’s why eight European organisations - including flanders.bio - joined forces in the European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB). By building a European interconnected value chain, the #EHAB will identify regional strengths, weaknesses, gaps and needs. 🇪🇺 Stay updated on our progress in strengthening the European landscape in Advanced Therapies and Biomaterials (AT&B) by following the EHAB page! ☝🏼 🫱🏽🫲🏾 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 BOM (Brabantse Ontwikkelings Maatschappij) (🇳🇱) - Brightlands Maastricht Health Campus (🇳🇱) - BioRegio STERN Management GmbH (🇩🇪) - A4TEC Association (🇵🇹) - Biocat, BioRegion of Catalonia (🇪🇸) - RISE Research Institutes of Sweden (🇸🇪) - MedSilesia Cluster - Silesian Medical Devices Network (🇵🇱) - flanders.bio (🇧🇪) 🙌🏽 𝗘𝗻𝗱𝗼𝗿𝘀𝗲𝗿𝘀 Provincie Noord-Brabant - Provincie Limburg - RegMed XB - Departement Economie, Wetenschap en Innovatie (EWI) - Vanguard Initiative - Generalitat de Catalunya - Leitat Technological Center - AseBio - Asociación Española de Bioempresas - Vall d'Hebron Institute of Oncology (VHIO) - Fraunhofer IPA. Funded by the European Union.
To view or add a comment, sign in
-
-
FRESH OFF THE PRESS - SwedenBIO’s "Life Science Barometer 2024" is out - a snapshot of the Swedish Life Science industry is out with impressive facts & figures and an overview of the Nordic Life Science by numbers! Some of the impressive facts: ✅ A total of 4,000 Swedish life science companies of which 1/3 are public listed! ✅ Of the 4,000 companies 54% are located in the Stockholm/Uppsala region 21% (892) in the Swedish part of Medicon Valley and 16% around Göteborg. ✅ A big majority of Medtech companies 61% followed by Pharma of 31% and biotech of 19%. ✅ Without a doubt the focus and investment with growth, R&D and innovation calls for an increasing demand for talent. Other fresh figures are the Gender Balance in the Swedish life science industry – which the Swedes may not be proud of – but I as a Dane am impressed and applaud 👏 Of the 200 life science companies engaged in the survey, they had: ✅ 42% women in top management and ✅ 30% women in boards. VILDA - Ledande kvinnor i Life Science Women in Life Science Denmark When it comes to the Biopharma pipeline - the Nordics again punches above its our weight. The collective Nordic R&D drug pipeline has risen 50% over the last decade to more than 900 assets with Sweden being the largest contributor to the asset pipeline within the Nordics. Sweden has 130 separate companies with active drug development programs, with more than 400 drugs. Biologics and RNA therapies, rare diseases and immunology – these are all areas of notable investment. A legacy of neuroscience and cardiometabolic research continues as Nordic companies remain global leaders in the field. Even cell therapy, where the domestic pipeline is slightly under the 4% share, is rapidly becoming an area of strength with a 50% increase in the last year alone! Sweden and Denmark being the drivers within life science - imagine what we could do – if we on stronghold or up-and-coming areas like the ATMP joint forces and maybe even dared to commit ourselves in our national life science strategies. At Medicon Valley Alliance, we have great examples of strong Swedish-Danish collaborations and we are all in for supporting more. Read more about this brilliant report here: https://lnkd.in/dmzRVvhX Maja Neiman 👏 Jessica Martinsson Citeline Jean-Marc Mezin Daniel Chancellor Medicon Village Sahlgrenska Science Park Stockholm Science City Lene Gerlach
To view or add a comment, sign in
-
-
An amazing line-up of speakers. Don't miss this once-in-a decade event. @BMH2024Melb covers Themes such as # RNA_Technology, #Gene_Editing, #Climate_Change, # Synthetic_Biology, #Structural_Biology, #Genome, #Cancer, #Infection, #Education, #Molecular basis of Disease. See you in Melbourne, Australia in September 2024. The Future in BioMolecular!
🌐 This is more than just a Congress - it's a global forum... Join us in Melbourne for an extraordinary event that unites the brightest minds in biomolecular science! We are proud to introduce our diverse lineup of invited plenary speakers from across the world. 🌟 These leaders in the biomolecular field are from renowned institutions, spanning continents and specialties. They bring with them insights from years of groundbreaking research and innovation. Their expertise covers a vast array of subjects, from immunotherapy to protein design, molecular physiology, and beyond. Don’t miss this opportunity to engage with international specialists who are shaping the future of biomolecular science. 🧬🔬 Get ready to be inspired, learn, and connect. See you in Melbourne for a truly global scientific exchange! Register here: www.bmh2024.com.au #BiomolecularHorizons2024 #bmh2024 #GlobalScienceLeaders #MelbourneConference University of Zurich Chinese Academy of Sciences WEHI (Walter and Eliza Hall Institute of Medical Research) Afrigen Biologics (Pty) Ltd Stanford University Harvard University Massachusetts Institute of Technology
To view or add a comment, sign in
-